v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenues
Operating expenses:      
Research and development expenses, net (note 17a) 10,623 19,012 18,693
General and administrative expenses (note 17b) 4,913 6,139 7,104
Other expenses (note 17c) 352 4,244
Total 15,888 29,395 25,797
Operating loss (15,888) (29,395) (25,797)
Finance income (expenses), net (note 17d) 874 327 (5,263)
Net loss (15,014) (29,068) (31,060)
Other comprehensive gain      
Total other comprehensive gain
Total comprehensive loss $ (15,014) $ (29,068) $ (31,060)
Basic loss per share (in Dollars per share) $ (0.73) $ (1.56) $ (1.69)
Diluted loss per share (in Dollars per share) $ (0.73) $ (1.56) $ (1.69)
Weighted average number of shares outstanding basic (in Shares) 20,513,992 18,574,484 18,394,886
Weighted average number of shares outstanding diluted (in Shares) 20,513,992 18,574,484 18,394,886